<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ N4P.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #ef4444 0%, #dc2626 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">N4P.L</div>
            <div class="company-name">N4 Pharma Plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£3,953,331</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 1234 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="font-size: 32px; font-weight: 800; color: white;">‚óâ AVOID</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">34</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">15</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #fee2e2; color: #991b1b;">BROKEN</span>
            </div>
            
            <div class="thesis-line">
                AVOID - BROKEN timing with 34/100 opportunity score
            </div>
        </div>

        <!-- ==================== CRASHDASH INTELLIGENCE - PANIC HUNTER VIEW ==================== -->
        
        <div class="card" style="background: linear-gradient(135deg, #f0fdf4 0%, #dcfce7 100%); border: 2px solid #84cc16;">
            <div class="card-title" style="color: #0f172a;">
                <span class="card-icon">üè≠</span>
                CrashDash Intelligence ‚Ä¢ Industrials
            </div>
            
            <!-- Fear Meter -->
            <div style="background: white; padding: 24px; border-radius: 14px; margin-bottom: 20px; text-align: center;">
                <div style="font-size: 16px; font-weight: 700; color: #1e293b; margin-bottom: 16px;">üî• PANIC METER</div>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-bottom: 16px;">
                    <div style="width: 160px; height: 160px; border-radius: 50%; background: conic-gradient(#84cc16 208.8deg, #e5e7eb 208.8deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                        <div style="width: 130px; height: 130px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                            <div style="font-size: 48px; font-weight: 800; color: #84cc16;">58</div>
                            <div style="font-size: 12px; color: #64748b; font-weight: 600;">PANIC SCORE</div>
                        </div>
                    </div>
                    <div style="text-align: left; max-width: 400px;">
                        <div style="font-size: 18px; font-weight: 700; color: #84cc16; margin-bottom: 12px;">MODERATE FEAR</div>
                        <div style="font-size: 14px; color: #475569; line-height: 1.6; margin-bottom: 12px;">üü° Cautious sentiment - assess risk/reward</div>
                        <div style="font-size: 13px; color: #64748b;">
                            <div>üíî Price: 40/40</div>
                            <div>üìâ Volume: 10/20</div>
                            <div>üîá Social: 6/20</div>
                            <div>üì∞ News: 2/20</div>
                        </div>
                    </div>
                </div>
                
                <!-- CrashHunter Signals -->
                <div style="margin-top: 20px;">
                    <span style="display: inline-block; background: #ef4444; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">‚ùå Broken</span><span style="display: inline-block; background: #64748b; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">‚ùì Conf 15</span>
                </div>
                
                <!-- Opportunity Flag -->
                
            </div>
            
            <!-- Contrarian Compression Energy Panel -->
            
            <!-- Contrarian Compression Energy Panel -->
            <div style="background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); padding: 24px; border-radius: 14px; margin-bottom: 20px; border: 3px solid #10b981;">
                <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 20px;">
                    <span style="font-size: 32px;">‚ö°</span>
                    <div style="flex: 1;">
                        <div style="font-size: 20px; font-weight: 800; color: #0f172a; margin-bottom: 4px;">
                            CONTRARIAN COMPRESSION SCORE
                        </div>
                        <div style="font-size: 13px; color: #475569; font-weight: 600;">
                            Signal Congestion Framework ‚Ä¢ Compression = Explosive Potential
                        </div>
                    </div>
                </div>
                
                <!-- Main Score Display -->
                <div style="background: white; padding: 24px; border-radius: 12px; margin-bottom: 20px; text-align: center;">
                    <div style="display: flex; justify-content: center; align-items: center; gap: 30px;">
                        <!-- Circular gauge -->
                        <div style="width: 140px; height: 140px; border-radius: 50%; background: conic-gradient(#10b981 64.8deg, #e5e7eb 64.8deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                            <div style="width: 110px; height: 110px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                                <div style="font-size: 42px; font-weight: 800; color: #10b981;">18</div>
                                <div style="font-size: 11px; color: #64748b; font-weight: 600;">/ 100</div>
                            </div>
                        </div>
                        
                        <!-- Key metrics -->
                        <div style="text-align: left;">
                            <div style="font-size: 16px; font-weight: 700; color: #10b981; margin-bottom: 12px;">‚ö™ LOW COMPRESSION (Early/Weak)</div>
                            <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                                <div><strong>0.7</strong> signals/week</div>
                                <div><strong>0</strong> RSI &lt; 20 events</div>
                                <div><strong>0</strong> escalations detected</div>
                                <div style="color: #10b981; font-weight: 700; margin-top: 6px;">
                                    üíé Historical pop: <strong>+118%</strong>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Component Breakdown -->
                <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 15px;">
                        üìä 5-COMPONENT BREAKDOWN
                    </div>
                    
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">compression</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">8/40</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 20.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">0.7 signals/week | üéØ MILD COMPRESSION</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">intensification</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/20</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 25.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;"></div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">volume death</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Normal volume</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">pop potential</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 33.33333333333333%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Baseline mover (118%)</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">accumulation</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/10</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">No accumulation</div>
                </div>
                
                </div>
                
                <!-- Contrarian Philosophy -->
                <div style="background: rgba(255,255,255,0.7); padding: 16px; border-radius: 10px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #0f172a; margin-bottom: 8px; font-size: 14px;">
                        üéØ CONTRARIAN WISDOM
                    </div>
                    <div style="font-size: 13px; color: #334155; line-height: 1.6;">
                        <strong>Signal congestion = Compression energy = Explosive potential.</strong><br>
                        When multiple crash signals cluster together with extreme RSI and proven rally history, 
                        it creates a compressed spring effect. More panic = More opportunity for contrarians.
                        <div style="margin-top: 8px; padding: 10px; background: rgba(239,68,68,0.1); border-radius: 6px; font-size: 12px;">
                            <strong style="color: #10b981;">Theory:</strong> High compression scores (60+) historically precede 
                            explosive 10-20x moves when catalysts arrive. This is the foundation of crash hunting.
                        </div>
                    </div>
                </div>
            </div>
            
            
            <!-- Fear vs Facts Contrarian View -->
            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px; margin-bottom: 20px;">
                <div style="background: #fee2e2; padding: 18px; border-radius: 12px; border-left: 4px solid #ef4444;">
                    <div style="font-weight: 700; color: #991b1b; margin-bottom: 12px; font-size: 15px;">üò± FEAR (What Panic Shows)</div>
                    <div style="color: #7f1d1d;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üíî Price destruction: 40/40 points</div>
                    </div>
                </div>
                <div style="background: #dcfce7; padding: 18px; border-radius: 12px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #065f46; margin-bottom: 12px; font-size: 15px;">üìä FACTS (What Data Shows)</div>
                    <div style="color: #064e3b;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üìà Historical upside: 118% proven capacity</div><div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üí∞ Deep value: 73% off recent peak</div>
                    </div>
                </div>
            </div>
            
            <!-- Contrarian Verdict -->
            <div style="background: white; padding: 18px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #4338ca; margin-bottom: 10px; font-size: 15px;">‚öñÔ∏è Contrarian Verdict</div>
                <div style="font-size: 15px; color: #1e293b; line-height: 1.6; font-weight: 600;">
                    ‚úÖ Facts align with low fear - Normal risk/reward
                </div>
            </div>
            
            <!-- Industry Crash Patterns -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin-bottom: 20px;">
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">‚ö†Ô∏è Crash Patterns (Industrials)</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book decline or cancellations</div><div>‚Ä¢ Margin compression (input costs)</div><div>‚Ä¢ Cyclical demand weakness</div>
                    </div>
                    <div style="margin-top: 12px; padding: 10px; background: #fef3c7; border-radius: 8px; font-size: 12px; color: #92400e; font-weight: 600;">üö® Active: Project delays or overruns</div>
                </div>
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">üöÄ Recovery Paths</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book growth or new contracts</div><div>‚Ä¢ Margin recovery (efficiency gains)</div><div>‚Ä¢ Cyclical upturn (capex recovery)</div>
                    </div>
                </div>
            </div>
            
            <!-- Catalyst Pipeline -->
            <div style="background: rgba(255,255,255,0.5); padding: 18px; border-radius: 12px; margin-bottom: 20px;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 14px; font-size: 15px;">üìÖ Catalyst Pipeline</div>
                
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Business and Operational Update</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Interim Results</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Partnership with University of Strathclyde‚Äôs CMAC</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">N4 Pharma‚Äôs Nuvec¬Æ Targets Lung Cancer Cells</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Notice of Results, Analyst & Investor Presentation</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            </div>
            
            <!-- CrashDash Decision Matrix -->
            <div style="background: white; padding: 20px; border-radius: 12px; border: 3px solid #84cc16;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 16px; text-align: center;">
                    üéØ CRASHDASH DECISION: <span style="color: #84cc16; font-size: 20px;">AVOID</span>
                </div>
                <div style="font-size: 15px; color: #475569; text-align: center; margin-bottom: 20px; font-weight: 600;">
                    ‚ùå AVOID - timing BROKEN
                </div>
                <div style="background: #f8fafc; padding: 16px; border-radius: 10px;">
                    <div style="font-weight: 700; color: #64748b; margin-bottom: 12px; font-size: 13px;">CHECKLIST (1/5 pass)</div>
                    
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üü¢</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Panic Score</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">58/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ùå</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Timing Regime</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">BROKEN</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ö†Ô∏è</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">APEX Quality</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">34/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ùì</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Data Confidence</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">15/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üè≠</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Industry Pattern</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">1 active</div>
                </div>
            </div>
            
                </div>
            </div>
        </div>
        

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 34/100 indicates moderate opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: BROKEN</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 2 rallies, 118% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 15/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Moderate Technical Setup</strong><br><small>Chart quality: 8/20 ‚Ä¢ Score: 10/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 82.6% from peak ‚Ä¢ Score: 17/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Above average volume</strong><br><small>1.7x average ‚Ä¢ Score: 6/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Limited history</strong><br><small>2 previous rallies ‚Ä¢ Score: 5/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Good upside</strong><br><small>Historical best: +118% ‚Ä¢ Score: 8/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">-73%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">118%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">-0.6x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Deep drawdown - thesis failing</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">current return=-72.7% ‚Ä¢ timing=BROKEN</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Round-trip collapse - pump and dump pattern</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True ‚Ä¢ current return=-72.7%</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical ‚Ä¢ signal date=2022-09-05</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Avoid</div>
                    <div style="font-size: 14px; opacity: 0.9;">Do not trade - thesis invalidated</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">0%</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">N/A</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">N/A</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows BROKEN timing with 34/100 APEX score. Historical data shows 2 rallies averaging 118% upside. Current position: -72.7%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Limited upside case without catalysts</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Deep drawdown (-72.7%) suggests broken thesis</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Thesis invalidated. Avoid or exit.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 15/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Business and Operational Update</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">17th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Pharma Investor</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
17 Dec 2025 07:00
RNS Number : 8212L
N4 Pharma PLC
17 December 2025
17 December 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Business and Operational Update
N4 Pharma plc (AIM: N4P),
the UK biotech developing Nuvec¬Æ, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases
,
is pleased to provide an operational update and business review.
University of Strathclyde collaboration
The Company's collaboration with the Centre for Continuous Manufacturing and Advanced Crystallisation ("CMAC"), the
world-leading research institute in the field of nanoparticle drug delivery
, based at the University of Strathclyde, is progressing well. The programme remains on track towards key
in vitro
and
in vivo
studies planned for the first half of 2026, and to build out the commercial data to demonstrate Nuvec¬Æ's key benefits and advance Nuvec¬Æ towards clinical readiness.
As part of this programme, drug-loading procedures are being established to optimise reproducibility, efficiency and stability, and direct comparisons are being made with lipid nanoparticles, the current industry standard, to demonstrate the competitive benefits of Nuvec¬Æ.
Latest studies indicate that Nuvec¬Æ nanoparticles would offer a significant commercial advantage over lipid nanoparticles ("LNPs"), particularly in terms of stability. This includes both the intrinsic stability of the nanoparticle itself and the stability achieved following loading with siRNA.
All this work is essential both for the development of N4 101, an oral anti-inflammatory product for the treatment of Inflammatory Bowel Disease ("IBD"), and any potential partnership collaborations
for Nuvec¬Æ more generally,
as it lays the foundation for any future clinical work by N4 Pharma or by partners.
2025 highlights
In addition to the crucial CMAC work above, the Company has made further excellent progress towards the key objectives set out
following the April 2025 fundraising
, focused on building out the Nuvec¬Æ data set to support future commercial outreach.
Key achievements include:
¬∑
Successful preclinical demonstration of oral delivery and efficacy
using Nuvec¬Æ in an animal model of IBD. The protection of the RNA payload by Nuvec¬Æ represents a key differentiator versus competing delivery technologies.
¬∑
Successful targeting of Nuvec¬Æ particles
,
demonstrated both in the IBD programme and in work conducted with SRI International in non-small cell lung cancer ("NSCLC") cells. Effective targeting is widely regarded as the 'holy grail' for pharmaceutical companies developing RNA-based therapeutics.
Anticipated newsflow
The Company expects a strong flow of data-driven news in the coming months, including:
¬∑
Further comparative performance data for Nuvec¬Æ versus lipid nanoparticles, which currently dominate RNA therapeutic delivery but suffer from known drawbacks, including toxicity, limited targeting capability and manufacturing complexity.
¬∑
In vivo
biodistribution and further targeting data
will provide critical insights into where Nuvec¬Æ distributes within the body and further demonstrate how it can be directed to specific tissues.
¬∑
Repeat of N4 101
in vivo
study using two siRNA to reduce inflammation
.
¬∑
Identification of assets that N4 Pharma will look to develop itself into clinical trials, clearly positioning the Company as an RNA therapeutic company as well as having a unique delivery platform.
Intellectual property
The Company has also strengthened its intellectual property position with the PCT filing of its patent application relating to its IBD programme. The patent now covers the use of Nuvec¬Æ for the delivery of dual-loaded siRNA therapies as well as combined siRNA and mRNA payloads.
N4 Pharma has also been notified that the Japanese patent office has issued a notice to allow the grant of its patent application for the use of Nuvec¬Æ to improve the performance of viral vectors and now awaits the formal notification of this application being granted in Japan. This patent is still being prosecuted in the USA and Europe.
Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:
"We are very encouraged by the progress being made across the Nuvec¬Æ programme and by the data emerging from our collaboration with the University of Strathclyde. The stability, targeting and oral delivery data generated to date reinforce our belief that Nuvec¬Æ has the potential to address several of the key limitations associated with lipid nanoparticles, which remain the current industry standard.
"N4 Pharma is building a robust, high-quality data package to support future commercial discussions. With multiple important readouts expected in the coming months, we believe Nuvec¬Æ continues to demonstrate its potential as a differentiated and commercially attractive delivery platform for RNA therapeutics and will provide the Company further opportunities to look at developing its own RNA assets in the future."
- Ends -
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub
https://n4pharma.com/link/yaGp6r
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
Guy McDougall
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec¬Æ, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec¬Æ has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,
protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec¬Æ platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec¬Æ platform.
For further information on the Company visit
www.n4pharma.com
or sign up at
https://investors.n4pharma.com/auth/signup
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
UPDQQLFFELLLFBZ
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Interim Results</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">POSITIVE RESULTS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Positive development - monitor for follow-through in share price.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">25th Sep 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">These Condensed</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">78%, 3.9%, 50%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
25 Sep 2025 07:00
RNS Number : 6969A
N4 Pharma PLC
25 September 2025
25 September 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Interim Results
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec¬Æ, i
ts proprietary drug delivery system to enable advanced nucleic acid therapies for cancer and other diseases,
today
announces its unaudited interim results for the six months ended 30 June 2025.
Highlights:
¬∑
Reduced operating loss for the period to
¬£470,216 (30 June 2024: ¬£491,705) and R&D and general expenditure in line with budget.
¬∑
Cash position remains strong, which
at 30 June 2025 was
¬£
1,727,543
(30 June 2024: ¬£
1,204,946
),
following a successful placing in April 2025 to raise gross proceeds of ¬£1,750,000.
¬∑
Positive results from first
in vivo
efficacy¬†study for N4 101 using an industry standard animal model of IBD showing a marked decrease in inflammation with¬†both single and¬†dual-loaded Nuvec¬Æ particles compared with controls across all key indicators of ulcerative colitis, including Disease Activity Index (DAI), colon length and body weight loss and a clear increase in efficacy using Nuvec¬Æ particles targeted to macrophages using mannose.
¬∑
Appointment of Dr Alastair Smith as an independent Non-Executive Director in January 2025 and¬†Edward Wardle as Non-Executive Director post period end.
¬∑
World-class Senior Leadership Team established with leading expert consultants in drug development and research, commercial strategy and pharmaceutical manufacturing in May 2025.
¬∑
Analysis of data from collaboration with
world-renowned nonprofit R&D institute SRI International
("SRI") demonstrates the ability
to specifically target
cancer
cells for the delivery of RNA using Nuvec¬Æ,
which
opens a massive market for targeted treatments in oncology.
¬∑
Post
-
period collaboration with
CMAC
,
based at the University of Strathclyde in Glasgow, to focus on advancing the Nuvec¬Æ platform towards clinical readiness and characterising additional dual-loaded Nuvec¬Æ preclinical candidates, both
in vitro
and
in vivo.
Nigel Theobald, Chief Executive Officer of N4 Pharma plc, commented:
"The first half of the year has delivered strong progress with N4 Pharma's focus being on expanding the team to formalise the Company's data package with a view to securing commercial agreements with third parties, whilst advancing its lead preclinical programme, N4 101, and scoping out novel RNA drug development opportunities with Nuvec¬Æ.
"
Following the Company's successful fundraising in April 2025, N4 Pharma is well placed to undertake the work required to hit key value inflection milestones, building on
Nuvec's¬Æ proven ability in the use of oral and targeted drug delivery, two areas which represent, both in unison and individually, areas of massive commercial potential
.
The Company is delighted to have partnered with CMAC as a world-leading research institute in the field of nanoparticle drug delivery to further expand N4 Pharma's data to support deal-making and drug development."
Analyst briefing
An online briefing for analysts will be hosted by
Nigel Theobald, Chief Executive Officer,
at 9.30 am on
Thursday, 25 September 2025
, to review the interim results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at
sarah@northstarcommunications.co.uk
.
Investor presentation
An investor presentation to cover the interim results will be held at 2.00 pm on
Thursday, 25 September 2025
.
The presentation is open to all existing and potential shareholders, and questions can be submitted at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet¬†N4 Pharma plc¬†via:
https://www.investormeetcompany.com/n4-pharma-plc/register-investor
Investors who already follow¬†N4 Pharma plc¬†on the Investor Meet Company platform will automatically be invited.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.
- Ends -
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:
investors.n4pharma.com
https://n4pharma.com/link/rLwMGe
.
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896
About N4 Pharma
N4 Pharma is a preclinical biotech company developing Nuvec¬Æ, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec¬Æ has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec¬Æ platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec¬Æ platform.
For further information on the Company visit
www.n4pharma.com
or sign up at
https://investors.n4pharma.com/auth/signup
.
Chairman's Statement
Half year financial results
I am pleased to report N4 Pharma's financial results for the six months ended 30 June 2025. During the period, ¬£3,690 of revenue was generated by the Group (30 June 2024: ¬£3,906).
The loss for the period was ¬£470,216 (30 June 2024: ¬£491,705) and in line with planned expenditure.
The Company's cash balance at 30 June 2025 was ¬£1,727,543 (30 June 2024: ¬£1,204,946), following a successful placing to raise gross proceeds of ¬£1,750,000 in April 2025.
Operational update
The first half of the financial year has been about ensuring that the Company has the right team and finance in place to rapidly advance the Nuvec¬Æ platform with a view to securing commercial partners as quickly as possible. N4 Pharma has also continued the preclinical development of the Company's lead product, N4 101, following the first successful
in vivo
study results during the period, which confirmed that
Nuvec¬Æ has the potential to deliver an oral inflammation therapeutic for the treatment of GI disorders, including Inflammatory Bowel Disease ("IBD") and Ulcerative Colitis ("UC").
N4 Pharma is increasingly aware of the strengths of
Nuvec¬Æ, in particular its ability to target the RNA payload to specific cells, which is a key requirement for RNA therapeutics developers, and this has directed the Company's corporate strategy to deliver maximum value for shareholders. The Company believes that the ability to specifically target certain cell types is a major differentiator compared to other delivery systems.
The Company's resources will be focused in the near term on expanding N4 Pharma's data to support deal-making whilst continuing to advance N4 101 as a potential clinical candidate as well as a model system to exemplify Nuvec¬Æ's key benefits. N4 Pharma is also carrying out initial work to identify further novel RNA therapeutic opportunities to expand the Company's in-house pipeline.
The key benefits of Nuvec¬Æ as a delivery platform are:
¬∑
Its unique, patented spiky surface structure allows the loading of both DNA and RNA drugs and protects them from degradation;
¬∑
It is relatively straightforward to manufacture and scale up;
¬∑
It can be targeted to specific cells such as cancer and immune cells to reduce toxicities and broaden the range of applications of nucleic acid therapies;
¬∑
In contrast to other delivery options such as viral vectors and lipid nanoparticles, which are known to evoke an immune response, the inert nature of Nuvec¬Æ nano-silica particles dramatically reduces immunogenicity at the concentrations used
;
¬∑
It is a straightforward process to load multiple siRNAs onto the same nanoparticle for combination therapies;
¬∑
High loading capacity, efficient cellular uptake and endosomal release enables delivery of large numbers of RNA copies into each cell; and
¬∑
Its protective capabilities allow for oral delivery of nucleic acid therapies.
Lead preclinical programme - N4 101, a potential oral treatment for inflammatory bowel disease (IBD)
Following the successful completion of
in vitro
profiling in December 2024, during the period under review, the Company completed its first
in vivo
study using an industry-standard mouse model of IBD. The study explored the therapeutic potential of orally administered Nuvec¬Æ particles loaded with siRNA alone and combined with mRNA.
Over a nine-day dosing period, mice with chemically induced acute IBD received single (siRNA) or dual (siRNA and mRNA) Nuvec¬Æ-loaded formulations with the Nuvec¬Æ particles modified to specifically target cells involved in gut inflammation. Samples were collected for analysis on day 15.
Key highlights from the study included:
¬∑
Reduction in inflammation:
both single and
dual-loaded Nuvec¬Æ particles demonstrated marked improvements compared with controls across all key indicators of colitis, including Disease Activity Index (DAI), colon length, and body weight loss.
¬∑
Marked increase in efficacy achieved with targeting:
both the single and dual loaded Nuvec¬Æ combined with a targeting agent performed better and showed an even greater reduction in the inflammatory marker TNF alpha than the untargeted therapies.
¬∑
Sustained therapeutic effect:
six days after the final administration, both single and dual-loaded targeted Nuvec¬Æ particles showed a near complete reduction in TNF alpha levels in intestinal tissues.
¬∑
Effective oral delivery:
the study also provides clear
in vivo
evidence that Nuvec¬Æ particles successfully deliver therapeutic nucleic acid cargos (siRNA and mRNA) to the gut via oral administration, resulting in the sustained anti-inflammatory effects observed.
N4 Pharma believes the market for such an oral product to treat GI inflammation to be significant. Current therapies for immune-mediated inflammatory diseases, such as IBD, are sub-optimal, requiring regular, painful injections which can result in reduced patient compliance. Injectable products to treat these disorders represented 78% of a market worth US
$20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over US$27.6bn by 2030¬π
.
The ability to deliver a medication orally targeting the same mechanism as the antibody-based therapeutics would represent a preferable form of treatment. With 5 million sufferers of the two main types of IBD (Crohn's disease and ulcerative colitis), there is huge potential for a product to address this market and it is estimated that the oral segment of this market could be worth US$7bn by 2030.
There is a significant market opportunity for such a product, mainly as an oral substitute for the largest sector already of TNF inhibitors and to compete with the inhibitor drugs being developed. If such a product could take 50% share of the existing TNF inhibitor market and 25% of the oral market, it would potentially be worth US$12bn. Even achieving just 10% of this at US$1.2bn would give the product significant potential.
(¬π 2023 Grand View Research, Inc. Inflammatory Bowel Disease Treatment. Market Analysis, 2018-2030).
To date, the Company has worked closely with the University of Queensland ("UQ"), who were the original inventors of the Nuvec¬Æ technology. With the emphasis now on creating a data package more geared towards commercial collaborations the Company is migrating the ongoing work to a specialist contract research organisation, CMAC at Strathclyde University.
The focus of the work at CMAC over the next six to nine months is to:
¬∑
develop a scalable and reproducible dual siRNA loading process;
¬∑
fully characterise the loaded nanoparticles
(physicochemical, cell-based);
¬∑
assess different surface coatings;
¬∑
generate stability data;
¬∑
conduct an oral biodistribution study;
¬∑
generate comparisons with competitive platforms such as lipid nanoparticles; and
¬∑
explore other targeting moieties.
Targeting cells in Oncology
As recently announced, following the successful work with SRI combining its targeting molecules with Nuvec¬Æ to successfully deliver
therapeutic RNA ("siRNA") payloads to non-small cell lung cancer cells the Company is developing a work programme to explore novel siRNA oncology targeting.
The key results from the SRI work showed:
¬∑
Precision targeting achieved
: Nuvec¬Æ particles were modified with a molecule binding to Œ±vŒ≤6 - a protein found at high levels in epithelial cancers such as lung, breast, prostate and pancreatic adenocarcinomas.
¬∑
Selective uptake confirmed
: siRNA payloads were successfully delivered only by the modified Nuvec¬Æ particles, with no uptake in controls, demonstrating that Nuvec¬Æ can be directed to specific cell types.
¬∑
Broader validation of Nuvec¬Æ
: The findings strengthen the platform's potential as a differentiated delivery system for RNA therapeutics across multiple disease areas.
Targeting RNA therapies to specific cells and tissues to maximise efficacy and reduce systemic toxicity is highly sought after by nucleic acid therapeutics developers and is challenging to achieve with established RNA delivery methods.
The ability to demonstrate the successful targeting of Nuvec¬Æ to cancer cells and immune cells, as the Company is doing in its lead, N4 101, programme, is something we believe sets Nuvec¬Æ apart from other delivery systems and, as N4 Pharma's data package increases, will attract partners in these multi-billion dollar sectors.
Legacy programme - Liptide¬Æ Glaucoma product, ECP105
N4 Pharma has a legacy siRNA programme (ECP105) which is designed to be a simple and effective anti-fibrotic therapeutic approach which maximises and increases surgical success in the treatment of Glaucoma by reducing post-surgical scarring whilst avoiding exposing patients to the risk of cytotoxic medication. ECP105 uses Liptide¬Æ as a delivery system and contains a siRNA sequence to silence the fibrotic gene MRTF-B without cytotoxic side effects. The programme is being developed by Nanogenics Limited ("Nanogenics"), the Company's 71% owned subsidiary.
As previously announced, the Company submitted an application for orphan drug designation in respect of ECP105 to the U.S. Food and Drug Administration ("FDA"), for the prevention of scarring following glaucoma surgery and this process is still ongoing. However, additional work is required, and the Company is awaiting quotes and scopes of work for this work to advance ECP105. When the ongoing costs of the ECP105 programme are known, the Board will take a view as to which direction would be most beneficial for its interest in Nanogenics.
Board and management
In January 2025, David Templeton retired and stepped down from the Board. As stated at the time, on behalf of all Directors, the Company would like to thank him for his contributions over the years and wish him well for the future.
At the same time, the Company welcomed Dr Alastair Smith to the Board as a Non-Executive Director. Alastair was the founder and former Chief Executive Officer of Avacta Group plc ("Avacta"), an AIM-quoted biotech company established as a spin-out from Leeds University in 2005 and listed on the London Stock Exchange AIM market in 2006.
Over his tenure, Avacta grew into a leading biotech company comprising two divisions: a clinical-stage oncology drug company advancing its proprietary pre|CISIONTM¬†tumour targeting platform¬†and a diagnostics business executing an M&A-led growth strategy in Europe focused on healthcare professionals.
Post period end, in July 2025, the Company appointed Edward Wardle as a Non-Executive Director representing the interests of Northern Standard Limited, which became our largest shareholder following the placing in April 2025.
As announced on 27 May 2025, the Company's newly configured Board is now supported by the formation of a Senior Leadership Team, reporting to Nigel Theobald, Chief Executive Officer,
comprising leading expert consultants in drug development and research, commercial strategy and pharmaceutical manufacturing. The team is made up as follows:
Dr Fiona McLaughlin - Head of Research and Development
Dr Fiona McLaughlin is a highly experienced oncology drug developer and independent consultant, bringing over 25 years of experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development. Fiona started her career at GSK and has subsequently held leadership positions in multiple biotech companies, including CSO of Avacta Therapeutics, VP New Opportunities at Algeta ASA (now Bayer), VP Translational Research at Antisoma plc and Director of Pre-clinical Development at BTG plc (now part of Boston Scientific). She is also a non-executive director of Hox Therapeutics.
Fiona received a PhD from the Haematology Department at Cambridge University and has a BSc in Biochemistry from Glasgow University.
Mark Edbrooke - Head of Strategy
Mark Edbrooke, PhD¬†is an independent scientific consultant with a broad experience in pharmaceutical research and¬†development. During 25 years at GlaxoSmithKline, he ran¬†a transnational functional genomics department and then set up¬†and led GSK's therapeutic nucleic acid unit. He then joined¬†AstraZeneca's Oncology Division for three years, working with Ionis and Moderna. Mark currently has a portfolio of clients, including UK and US-based investment companies,¬†UK and¬†European-based universities¬†and small¬†biotechs, including being Head of Translational Research at¬†Argonaute RNA Ltd. and on the Senior Advisory Board for Deep Genomics.
Dr Simon Bennett - Commercial Director
Dr Simon Bennett is an independent consultant with over 28 years of experience in the bio-pharma industry. Over the last 15 years, Simon has worked with more than 70 clients of all sizes, from technology startups to Big Pharma, largely supporting business development and licensing, as well as technology scouting and fundraising. Simon has been involved in over 80 commercial deals and mentors and advises early-stage businesses and management teams, primarily in specialty pharma and biotech. Before moving into industry in 1997, Simon was a Wellcome Trust Research Fellow at the University of Oxford.
Dr Margaret Courtney - Head of Chemistry, Manufacturing and Controls (CMC)
Dr Margaret Courtney is an independent consultant with over 25 years of experience in transitioning active substances and drug products from the research laboratory into clinical studies and commercialisation. Margaret has worked in management positions in small biotech companies to large pharmaceutical organisations and following on from her pharmacy degree and doctoral studies, has developed specific expertise in drug delivery systems. Currently, she is working with a range of clients and providing CMC strategic advice as well as selection and management of contract organisations.
Outlook and strategy
The commercial potential for a superior RNA delivery platform that could be widely adopted in the industry is very significant. The key benefits of the Nuvec¬Æ platform have been validated by a number of historical studies and an extremely experienced drug development team has now been put in place to complete this process and populate a commercial data room to support deal-making in the near term. Licensing deals with third-party RNA drug developers is a major value inflection point for the Company and remains a key objective.
Development of in-house RNA therapeutic candidates, differentiated by use of the Nuvec¬Æ platform, offers an opportunity to grow significant shareholder value beyond platform deals and the team is therefore advancing its lead programme, N4 101, a targeted treatment for IBD, by using it as a model system in the ongoing studies. N4 Pharma's recent success with SRI demonstrates a second targeting application, in this case non-small cell lung cancer cells. The Company expects the ability to target RNA therapeutics to be a key driver in N4 Pharma's conversations with potential license partners.
The Board strongly believes that the greatest return for shareholders will be delivered by a strong focus on the Nuvec¬Æ platform to deliver validation through commercial partnerships and grow longer-term value through its in-house pipeline.
On behalf of the Board, I would like to thank all of N4 Pharma's shareholders for their continued support and look forward to providing further updates on the Company's progress.
Chris Britten
Chairman
25 September 2025
Condensed Consolidated Interim Statement of Comprehensive Income (unaudited) for the six months ended 30 June 2025
Six months to 30 June 2025
Six months to 30 June 2024
Twelve months to 31 December 2024
(Unaudited)
(Unaudited)
(Audited)
¬£
¬£
¬£
Revenue
3,690
3,906
7,282
Gross profit
3,690
3,906
7,282
Expenses
Research and development costs
(67,316)
(114,030)
(390,387)
General and administration costs
(406,590)
(379,924)
(837,996)
Operating loss for the period
(470,216)
(490,048)
(1,221,101)
Finance (expenditure)/income
-
(1,657)
-
Loss for the period before tax
(470,216)
(491,705)
(1,221,101)
Taxation
(31,379)
-
101,112
Loss for the period after tax
(501,595)
(491,705)
(1,119,989)
Other comprehensive income net of tax
-
-
-
Total comprehensive loss for the period
(501,595)
(491,705)
(1,119,989)
Total comprehensive loss for the period is attributable to:
Equity owners of N4 Pharma Plc
(498,550)
(454,867)
(1,058,622)
Non-controlling interest
(3,045)
(36,838)
(61,367)
(501,595)
(491,705)
(1,119,989)
Loss per share attributable to owners of the parent
Weighted average number of shares:
Basic
576,550,109
285,395,734
340,386,906
Diluted
576,550,109
285,395,734
340,881,486
Basic loss per share
(0.09p)
(0.16p)
(0.31p)
Diluted loss per share
(0.09p)
(0.16p)
(0.31p)
All activities derive from continuing operations.
The notes below form an integral part of these financial statements.
Condensed Consolidated Interim Statement of Financial Position (unaudited) as at 30 June 2025
Notes
30 June 2025
30 June 2024
31 December 2024
(Unaudited)
(Unaudited)
(Audited)
¬£
¬£
¬£
Assets
Non-current assets
Goodwill
-
61,210
-
-
61,210
-
Current assets
Trade and other receivables
118,113
69,021
149,797
Cash and cash equivalents
1,727,543
1,204,946
625,972
1,845,656
1,273,967
775,769
Total Assets
1,845,656
1,335,177
775,769
Liabilities
Current liabilities
Trade and other payables
(28,263)
(11,613)
(28,796)
Accruals and deferred income
(50,104)
(44,428)
(95,571)
Total liabilities
(78,367)
(56,041)
(124,367)
Net current assets
1,767,289
1,217,926
651,402
Net Assets
1,767,289
1,279,136
651,402
Equity
Share capital
4
11,599,946
9,849,946
9,849,946
Share premium
5
14,736,767
14,940,829
14,940,829
Share option reserve
6
186,319
114,225
114,775
Reverse acquisition reserve
5
(14,138,244)
(14,138,244)
(14,138,244)
Merger relief reserve
5
279,347
279,347
279,347
Retained earnings
(10,897,556)
(9,796,134)
(10,399,006)
Non-controlling interest
9
710
29,167
3,775
Total Equity
1,767,289
1,279,136
651,402
The notes below form an integral part of these financial statements.
Condensed Consolidated Interim Statement of Changes in Equity (unaudited) for the six months ended 30 June 2025
(i) Six months ended 30 June 2025 - Unaudited
Share Capital
Share Premium
Share Option Reserve
Reverse Acquisition Reserve
Merger Relief Reserve
Retained Earnings
Non-controlling interest
Total Equity
¬£
¬£
¬£
¬£
¬£
¬£
¬£
¬£
Balance at 1 January 2025
9,849,946
14,940,829
114,775
(14,138,244)
279,347
(10,399,006)
3,755
651,402
Total comprehensive loss for the period
-
-
-
-
-
(498,550)
(3,045)
(501,595)
Share issue
1,750,000
-
-
-
-
-
-
1,750,000
Share issue cost
-
(204,062)
-
-
-
-
-
(204,062)
Share based payment charge
-
-
71,544
-
-
-
-
71,544
At 30 June 2025
11,599,946
14,736,767
186,319
(14,138,244)
279,347
(10,897,556)
710
1,767,289
(ii) Six months ended 30 June 2024 - Unaudited
Share Capital
Share Premium
Share Option Reserve
Reverse Acquisition Reserve
Merger Relief Reserve
Retained Earnings
Non-controlling interest
Total Equity
¬£
¬£
¬£
¬£
¬£
¬£
¬£
¬£
Balance at 1 January 2024
9,345,946
14,874,469
107,385
(14,138,244)
279,347
(9,341,267)
66,005
1,193,641
Total comprehensive loss for the period
-
-
-
-
-
(454,867)
(36,838)
(491,705)
Share issue
504,000
126,000
-
-
-
-
-
630,000
Share issue cost
-
(59,640)
-
-
-
-
-
(59,640)
Share based payment charge
-
-
6,840
-
-
-
-
6,840
At 30 June 2024
9,849,946
14,940,829
114,225
(14,138,244)
279,347
(9,796,134)
29,167
1,279,136
The notes below form an integral part of these financial statements.
(iii) Twelve months ended 31 December 2024 - Audited
Share Capital
Share Premium
Share Option Reserve
Reverse Acquisition Reserve
Merger Relief Reserve
Retained Earnings
Non-controlling interest
Total Equity
¬£
¬£
¬£
¬£
¬£
¬£
¬£
¬£
Balance at 1 January 2024
9,345,946
14,874,469
107,385
(14,138,244)
279,347
(9,341,267)
66,005
1,193,641
Total comprehensive loss for the year
-
-
-
-
-
(1,058,622)
(61,367)
(1,119,989)
NCI shares gifted back
-
-
-
-
-
883
(883)
-
Share issue
504,000
126,000
-
-
-
-
-
630,000
Share issue cost
-
(59,640)
-
-
-
-
-
(59,640)
Share based payment charge
-
-
7,390
-
-
-
-
7,390
At 31 December 2024
9,849,946
14,940,829
114,775
(14,138,244)
279,347
(10,399,006)
3,755
651,402
Condensed Consolidated Interim Statement of Cash Flows (unaudited) for the six months ended 30 June 2025
Six months to 30 June 2025
Six months to 30 June 2024
Twelve months to 31 December 2024
(Unaudited)
(Unaudited)
(Audited)
¬£
¬£
¬£
Operating activities
Loss after tax
(501,595)
(491,705)
(1,119,989)
Finance expenditure
-
1,657
-
Share based payments to employees
-
-
-
Share based payment charge
71,544
6,840
7,390
Taxation credit
31,379
-
(101,112)
Impairment of Goodwill
-
-
61,210
Operating loss before changes in working capital
(398,672)
(483,208)
(1,152,501)
Movements in working capital:
Decrease/ (increase) in trade and other receivables
305
118,024
(9,456)
(Decrease)/ increase in trade payables and accruals
(46,000)
(25,685)
42,641
Cash used in operations
(444,367)
(390,869)
(1,119,316)
Taxation credit received
-
-
147,816
Net cash flows used in operating activities
(444,367)
(390,869)
(971,500)
Financing activities
Finance expenditure
-
(1,657)
-
Proceeds of ordinary share issue
1,750,000
630,000
630,000
Costs of share issue
(204,062)
(59,640)
(59,640)
Net cash flows generated by financing
1,545,938
568,703
570,360
Net
increase/ (decrease) in cash and cash equivalents
1,101,571
177,834
(401,140)
Cash and cash equivalents at beginning of the period/ year
625,972
1,027,112
1,027,112
Cash and cash equivalents at period/ year end
1,727,543
1,204,946
625,972
The notes below form an integral part of these financial statements.
Notes to the Condensed Interim Consolidated Financial Statements for the six months ended 30 June 2025
1. Corporate Information
N4 Pharma Plc (the "Company"), is the holding Company for N4 Pharma UK Limited ("N4 UK"), and Nanogenics Limited ("Nanogenics"), and together form the group (the "Group"). N4 Pharma UK Limited is a specialist pharmaceutical company engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines.
Nanogenics is a specialist pharmaceutical company engaged in the development of a Liptide platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.
The Company was incorporated and registered in England and Wales on 6 July 1979 as a public limited company and its shares are admitted to trading on AIM (LSE: N4P). With effect from 15 May 2025 the Company's registered office was changed from 6th Floor, 60 Gracechurch Street, London, EC3V 0HR to C/o Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ.
The Condensed Interim Consolidated Financial Statements have been prepared in accordance with UK-adopted International Financial Reporting Standards and applied to the Company Accounts in accordance with the provisions of the Companies Act 2006.
The Condensed Consolidated Interim Financial Statements are presented in Great British Pounds ("GBP" or "¬£"), rounded to the nearest ¬£.
The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these condensed Interim Consolidated Financial Statements
2. Accounting Policies
Adoption of New and Revised International Financial Reporting Standards
There are no new standards or amendments effective in the period ended 30 June 2025 which have had a material impact.
Basis of Preparation:
The Group's condensed Consolidated Interim Financial Statements have been prepared in accordance with International Accounting Standard ("IAS") 34, "Interim Financial Reporting".
The annual Consolidated Financial Statements for the year ended 31 December 2024 were prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the United Kingdom.
The condensed consolidated interim financial information for the six months ended 30 June 2025 are unaudited. In the opinion of the Directors, the condensed consolidated interim financial information presents fairly the financial position, and results from operations and cash flows for the period.
These Condensed Consolidated Interim Financial Statements been prepared on the basis of accounting principles applicable to a going concern.
The Group prepares regular business forecasts and monitors its projected cash flows, which are reviewed by the Board. Forecasts are adjusted for reasonable sensitivities that address the principal risks and uncertainties to which the Group is exposed, thus creating a number of different scenarios for the Board to challenge. In those cases, where scenarios deplete the Group's cash resources too rapidly, consideration is given to the potential actions available to management to mitigate the impact of one or more of these sensitivities, in particular the discretionary nature of costs incurred by the Group, in order to ensure the continued availability of funds.
Basis of Consolidation:
The Group financial statements consist of the financial statements of the Company together with the entities controlled by the Company (its subsidiaries), N4 UK and Nanogenics.
The Condensed Consolidated Interim Financial Statements have been prepared as a result of the consolidation of the Company, N4 UK and Nanogenics, for the comparative six month period ended 30 June 2024 and the comparative twelve month period to 31 December 2024 and the current six month period ended 30 June 2025.
All intra-group transactions, balances and unrealised gains on transactions between Group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Subsidiaries are consolidated in the Group's financial statements from the date that control commences until the date that control ceases.
Significant Accounting Policies:
The Condensed Consolidated Interim Financial Statements have been prepared under the historical cost convention, as modified for the following items, in accordance with International Financial Reporting Standards ('IFRS') as adopted by the United Kingdom:
‚Ä¢ Share-based payments related to investment acquisition are measured at fair value shown in the Merger Reserve.
‚Ä¢ Share-based payments related to employee costs are measured at fair value at the date of grant shown in the Statement of Comprehensive Income.
‚Ä¢ Share-based payments related to share issue costs are measured at fair value at the date of grant shown in Share Premium.
‚Ä¢ The associated Share Options and Warrants are measured at fair value at the date of grant using the Black Scholes model (see note 6).
All accounting policies are consistent with those applied in the Annual Report and there have been no amendments or changes in accounting policies during the period.
Segmental reporting:
The Group operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec¬Æ and its liptide platform called ECP105.
The Directors consider that there are no identifiable business segments that are subject to risks and returns different to the core business. The information reported to the Directors, for the purposes of resource allocation and assessment of performance, is based wholly on the overall activities of the Group.
Seasonality
The nature of the business is not deemed to be impacted by seasonal fluctuations and as such performance is expected to be consistent.
3. Critical Accounting Judgements and Estimates
The preparation of the Condensed Consolidated Interim Financial Statements in conformity with IFRS requires management to make certain estimates, assumptions and judgements that affect the application of accounting policies and the reported amounts of assets and liabilities and the reported amounts of income and expenses during the reporting period. Actual results may differ from these estimates
Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.
In the process of applying the Group's accounting policies, the Directors have decided the following estimates and assumptions are material to the carrying amounts of assets and liabilities recognised in the condensed Consolidated Interim Financial Statements.
Critical judgements
Research and development expenditure
The key judgements surrounding the Research & Development expenditure is whether the expenditure meets the criteria for capitalisation. Expenditure will only be capitalised when the recognition criteria is met and is otherwise written off to the Consolidated Statement of Comprehensive Income. The recognition criteria include the identification of a clearly defined project with separately identifiable expenditure where the outcome of the project, in terms of its technical feasibility and commercial viability, can be measured or assessed with reasonable certainty and that sufficient resources exist to complete a profitable project. In the event that these criteria are met, and it is probable that future economic benefit attributable to the product will flow to the Group, then the expenditure will be capitalised.
4. Share Capital
Allotted, called up and fully paid
30 June 2025 (Unaudited)
30 June 2024 (Unaudited)
31 Dec 2024 (Audited)
¬£
¬£
¬£
832,280,349 Ordinary Shares of 0.4p each (30 June 2024: 394,780,349 and 31 December 2024: 394,780,349 Ordinary shares of 0.4p each)
3,329,121
1,579,121
1,579,121
137,674,431 Deferred Shares of 4p each
5,506,977
5,506,977
5,506,977
279,176,540 Deferred Shares of 0.99p each
2,763,848
2,763,848
2,763,848
11,599,946
9,849,946
9,849,946
All ordinary shares rank equally in all respects, including for dividends, shareholder attendance and voting rights at meetings, on a return of capital and in a winding-up.
During the period 247,500,000 new ordinary shares of 0,4p each were issued through a placing and 190,000,000 new ordinary shares of 0.4p each were issued through a subscription in April 2025 at a share price of 0.4p per share generating gross proceeds of ¬£1,750,000.
The 137,674,431 deferred shares of 4p, have no right to dividends nor do the holders thereof have the right to receive notice of or to attend or vote at any general meeting of the Company. On a return of capital or on a winding up of the Company, the holders of the deferred shares shall only be entitled to receive the amount paid up on such shares after the holders of the ordinary shares have received their return on capital.
The 279,176,540 deferred shares of 0.99p shall be entitled to receive a special dividend, which is payable upon the repayment to the Company of any amount owed under certain loan agreements, after which the Company shall, in priority to any distribution to any other class of share, pay to the holders of the Special Deferred Shares an aggregate amount equal to the amount repaid pro rata according to the number of such shares paid up as to their nominal value held by each shareholder. They shall be entitled to no other distribution save for a special dividend and shall not be entitled to receive notice of or attend or vote at a general meeting of the Company.
On a return of capital on a winding up of the Company, they shall only be entitled to receive the amount paid up on such shares up to a maximum of 0.99 pence per share after the holders of the Ordinary Shares and the Deferred Shares have received their return on capital.
5. Reserves
Merger relief reserve
The merger relief reserve arose on the Company's acquisition of N4 UK and consists of both the consideration shares and deferred consideration amounting to ¬£279,347. There is no legal share premium on the shares issued as consideration as section 612 of the Companies Act 2006, which deals with merger relief, applies in respect of the acquisition.
Reverse acquisition reserve
The reverse acquisition reserve arises due to the elimination of the Company's investment in N4 UK. Since the shareholder in N4 UK became a shareholder of the Company, the acquisition is accounted for as though the legal acquiree (N4 UK) is the accounting acquirer.
Share premium reserve
The share premium reserve comprises the excess amount received on the issue of ordinary shares by the Company in excess of their nominal value less issue costs
.
Share option reserve
The share option reserve comprises the fair value of options and warrants granted, less the fair value of lapsed and expired options and warrants.
Retained earnings
Retained earnings comprises of accumulated results to date.
6. Share-based Payments and Share Option Reserve
Options
The Company has the ability to issue options to Directors to compensate them for services rendered and incentivise them to add value to the Group's longer-term share value. Equity settled share-based payments are measured at fair value at the date of grant. The fair value determined is charged to the Consolidated Statement of Comprehensive Income on a straight-line basis over the vesting period based on the Group's estimate of the number of shares that will vest.
The vesting period is defined as the period in which the options are unable to be exercised. The period commences on the date the options are issued. For the options to vest, the holder must remain an employee of the Group throughout the vesting period. Once the vesting period is complete the options may be exercised on any date up to the lapse date.
Cancellations of equity instruments are treated as an acceleration of the vesting period and any outstanding charge is recognised in full immediately.
Fair value is measured using a Black Scholes pricing model. The key assumptions used in the model at the grant date were adjusted based on management's best estimate for the effects of non-transferability, exercise restrictions and behavioural considerations.
As at 30 June 2025, there were 26,329,370 (30 June 2024: 7,046,513, 31 December 2024: 22,046,513) options in existence over ordinary shares of the Company. Options in existence during the current and previous periods and year are as follows:
Name
Date of Grant
Ordinary shares under option
Vesting date
Expiry Date
Exercise Price ¬£
2015 Options
Gavin Burnell
14.10.15
1,351,210
14.10.15
14.10.25
2.8p
Luke Cairns
14.10.15
675,302
14.10.15
14.10.25
2.8p
2017 Options
Luke Cairns
03.05.17
717,143
03.05.20
03.05.27
7p
David Templeton
03.05.17
717,143
03.05.20
03.05.27
7p
Paul Titley
03.05.17
717,143
03.05.20
03.05.27
7p
2019 Options
Christopher Britten
21.05.19
717,143
21.05.22
21.05.29
3.55p
2020 Options
David Templeton
18.05.20
717,143
18.05.23
18.05.30
4.8p
Luke Cairns
18.05.20
717,143
18.05.23
18.05.30
4.8p
2024 Options
Nigel Theobold
27.11.24
2,000,000
27.11.25
27.11.34
0.75p
Michael Palfreyman
27.11.24
1,000,000
27.11.25
27.11.34
0.75p
Christopher Britten
27.11.24
1,000,000
27.11.25
27.11.34
0.75p
Luke Cairns
27.11.24
1,000,000
27.11.25
27.11.34
0.75p
Nigel Theobold
27.11.24
2,000,000
27.11.26
27.11.34
0.75p
Michael Palfreyman
27.11.24
1,000,000
27.11.26
27.11.34
0.75p
Christopher Britten
27.11.24
1,000,000
27.11.26
27.11.34
0.75p
Luke Cairns
27.11.24
1,000,000
27.11.26
27.11.34
0.75p
Nigel Theobold
27.11.24
2,000,000
27.11.27
27.11.34
0.75p
Michael Palfreyman
27.11.24
1,000,000
27.11.27
27.11.34
0.75p
Christopher Britten
27.11.24
1,000,000
27.11.27
27.11.34
0.75p
Luke Cairns
27.11.24
1,000,000
27.11.27
27.11.34
0.75p
2025 Options
Alastair Smith
08.01.25
1,666,666
08.01.26
08.01.35
0.75p
Alastair Smith
08.01.25
1,666,667
08.01.27
08.01.35
0.75p
Alastair Smith
08.01.25
1,666,667
08.01.28
08.01.35
0.75p
Total options
26,329,370
Each option entitles the holder to subscribe for one ordinary share in N4 Pharma Plc. Options do not confer any voting rights on the holder.
An amount of ¬£2,982 has been recognised in the Consolidated Statement of Comprehensive Income and in the Share Option Reserve in relation to the share options (30 June 2024: ¬£nil, 31 December 2024: ¬£550)
An amount of ¬£11,370 related to expired share options has been derecognised in the Consolidated Statement of Comprehensive Income and in the Share Option Reserve in relation to the share options (30 June 2024: ¬£nil, 31 December 2024: ¬£nil).
The aggregate fair value of the share options in issue as at 30 June 2025 was ¬£87,554 (30 June 2024: ¬£95,392, December 2024: ¬£95,941).
Warrants
As part of the placing in April 2025 which raised ¬£1,750,000 before fees and expenses, the Company issued 87,500,000 warrants at an exercise price of 0.4p per warrant to the Company's broker on the transaction as part of their fees.
The warrants entitle holders to subscribe for new ordinary shares at any time in the period of
60 months
following the grant of the warrants. The expiry date for the warrants is 4 April 2030.
Fair value is measured using a Black Scholes pricing model.
An amount of ¬£79,932 has been recognised in the Share Premium and in the Share Option Reserve in relation to the warrants (30 June 2024: ¬£6,840, 31 December 2024: ¬£6,840).
The number of warrants exercisable at 30 June 2025 end was 98,222,000 (30 June 2024: 10,722,000, December 2024: 10,722,000).
7. Earnings per Share
Basic earnings per share is calculated by dividing the loss after tax attributable (excluding the deemed cost of acquisition) to the equity holders of the Company by the weighted average number of shares in issue during the period.
Diluted earnings per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all potential dilutive shares, namely share options and warrants which could be bought for less than market price.
8. Interest in other entities
The Group's principal subsidiaries at 30 June 2025 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Group, and the proportion of ownership interests held equals the voting rights held by the Group. The country of incorporation or registration is also their principal place of business
.
Registered Office
Principal activity
Proportion of ownership and voting rights held
N4 Pharma UK Limited
The Mills, Canal Street, Derby, DE1 2RJ
Delivery of vaccines and therapeutics
100%
Nanogenics Limited
C/O Arch Law, Level 2 Huckletree,
8 Bishopgate,
London
EC2N 4BQ
Research and experimental development on biotechnology
71.21%
9. Non-controlling interest
Below is financial information for Nanogenics given that it has non-controlling interest that is material to the Group.
Statement of Financial Position
30 June 2025
¬£
30 June 2024
¬£
31 Dec 2024
¬£
Current Assets
28,549
106,805
47,365
Current liabilities
(26,081)
(6,849)
(34,320)
Current Net assets
2,468
99,956
13,045
Accumulated NCI
710
29,167
3,756
Statements of Comprehensive Income
30 June 2025
¬£
30 June 2024
¬£
31 Dec 2024
¬£
Revenue
3,690
3,906
7,282
Expenses
(9,697)
(130,151)
(235,164)
R&D Tax credit
(4,570)
-
14,727
Loss for the period
(10,577)
(126,245)
(213,155)
Loss allocated to NCI
(3,045)
(36,838)
(61,367)
10. Subsequent Events
Edward Wardle was appointed as a Non-Executive Director as of 8 July 2025.
There were no further significant subsequent events that require adjustment or disclosure in these condensed consolidated interim financial statements.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
IR PPUBABUPAGAC
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #10b98140;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #10b981 0%, #10b981dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">ü§ù</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Partnership with University of Strathclyde‚Äôs CMAC</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">CONTRACT WIN</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    New business win - potential revenue uplift for future quarters.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">23rd Sep 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #10b981;">BULLISH</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Pharma Investor</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
23 Sep 2025 07:00
RNS Number : 2764A
N4 Pharma PLC
23 September 2025
23 September 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Partnership with University of Strathclyde's CMAC National Facility
Collaboration combines N4 Pharma's innovative Nuvec¬Æ delivery platform with CMAC's world-class expertise to accelerate development and broaden therapeutic applications
N4 Pharma plc (AIM: N4P),
the UK biotech developing Nuvec¬Æ, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases
, is pleased to
announce a collaboration with CMAC
,
based at the University of Strathclyde in Glasgow.
CMAC
is a leading international manufacturing research centre with a unique configuration of academic research, applied projects and pre-competitive programmes. Working with industry partners, academic institutions and innovation collaborators, CMAC's mission is to transform
medicine development, manufacture and supply
.
This collaboration brings together the expertise of
Professor Yvonne Perrie, MBE
,
Head of the Strathclyde Institute of Pharmacy and Biomedical Sciences, alongside CMAC's National Facility team and N4 Pharma's scientific experts. The collaboration will focus on advancing the Nuvec¬Æ platform towards clinical readiness and characterising additional dual-loaded Nuvec¬Æ preclinical candidates, both
in vitro
and
in vivo
.
Professor Perrie is an internationally recognised authority in
drug delivery, RNA vaccines and nanomedicine manufacturing
,
combining academic leadership, regulatory expertise and extensive industry collaboration. She began her career with Lipoxen Technologies Ltd, developing liposomal drug delivery platforms before moving into academia, where she has built a leading research portfolio in advanced drug and vaccine delivery. She has published more than 150 papers, is an inventor on multiple patents and serves on the Scientific Advisory Board of Quotient Sciences. Professor Perrie is also a Commissioner on the UK's Commission on Human Medicines and has advised the MHRA, WHO and other international regulators. In 2024, she was awarded an
MBE for services to pharmaceutical innovation and regulation
.
Her work with industry partners is extensive. With AstraZeneca, she has led projects on lipid nanoparticle characterisation and advanced analytics. With GSK Vaccines Siena, she directed studies on cationic lipid nanoparticles for self-amplifying RNA vaccines and on how nanoparticle design influences vaccine potency. With Pfizer, she has collaborated through the CPI consortium on microfluidics and the Medicines Manufacturing Innovation Centre, advancing innovation in nanomedicine manufacturing.
Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:
"
We are delighted to partner with the University of Strathclyde and CMAC's National Facility. This collaboration builds upon excellent progress in our own programmes over the past few months and represents an important step in strengthening the commercial data package for Nuvec¬Æ, giving us access to world-class expertise and facilities to accelerate its development.
"
Working with Professor Perrie and the CMAC world-class scientists enhances our ability to characterise Nuvec¬Æ in depth, showcase its unique benefits and explore its broader therapeutic applications. These efforts bring us closer to our goal of positioning Nuvec¬Æ as a leading gene delivery platform for nucleic acid therapies, supporting both our internal pipeline and future licensing opportunities."
Professor Yvonne Perrie, MBE, added:
"We are excited to collaborate with N4 Pharma on the continued development of the Nuvec¬Æ platform. Our work at CMAC's National Facility is focused on advancing innovation in drug delivery and pharmaceutical manufacturing. Partnering with N4 Pharma provides an excellent opportunity to apply our expertise in RNA vaccines and nanomedicine manufacturing to help accelerate the Nuvec¬Æ programme towards clinical readiness and broaden its potential applications."
Massimo Bresciani, Industry Director of CMAC, commented:
"This project demonstrates the strength of industry-academic partnerships in accelerating medicines manufacturing. By combining N4 Pharma's innovative delivery platform with CMAC's technical expertise, we aim to unlock new possibilities in RNA therapeutics."
- Ends -
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:
investors.n4pharma.com
https://n4pharma.com/link/yEMX3y
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec¬Æ, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec¬Æ has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,
protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec¬Æ platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec¬Æ platform.
For further information on the Company visit
www.n4pharma.com
or sign up at
https://investors.n4pharma.com/auth/signup
.
About CMAC
CMAC is an internationally leading medicines manufacturing research centre with a unique configuration of academic research, applied and pre-competitive programmes.
Working in partnership with large pharma, technology providers, academic and innovation partners, CMAC's goal is to transform medicines development, manufacture and supply and further grow its pipeline of world-class multi-disciplinary collaborative research.
The centre's portfolio currently includes the Made Smarter Innovation: Digital Medicines Manufacturing Research Centre (DM¬≤), EPSRC international Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) collaboration, UKRPIF supported Net Zero Pilot and CMAC Data Lab, EPSRC CDT Cyber-physical Systems for Medicines Manufacturing (CEDAR), and the EPSRC MediForge Hub, along with training and translation projects within a world-class facility.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCPKBBDDBKDBCB
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">N4 Pharma‚Äôs Nuvec¬Æ Targets Lung Cancer Cells</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">22nd Sep 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Cancer Cells</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
22 Sep 2025 07:00
RNS Number : 0555A
N4 Pharma PLC
22 September 2025
22 September 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
N4 Pharma's Nuvec¬Æ Targets Lung Cancer Cells
Proof of targeted RNA delivery to non-small cell lung cancer cells achieved with SRI
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec¬Æ, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased
to announce
further details
of its collaboration with
world-renowned nonprofit R&D institute SRI
on the targeted delivery of RNA into cells using
Nuvec¬Æ. Following detailed additional analysis, the resulting data are now shaping a new scope of work focused on utilising
Nuvec¬Æ
for targeted treatments in oncology.
The Company's collaboration
combined
SRI's targeting molecules with Nuvec¬Æ
successfully delivering
therapeutic RNA ("siRNA") payloads to specific cell types, specifically non-small cell lung cancer cells.
Key results:
¬∑
Precision targeting achieved
: Nuvec¬Æ particles were functionalised with a targeting molecule binding to a cell surface adhesion molecule (Œ±vŒ≤6) - a protein found at high levels in epithelial cancers such as lung, breast, prostate and pancreatic adenocarcinomas
¬∑
Selective uptake confirmed
: siRNA payloads were successfully delivered and active only by the targeted Nuvec¬Æ particles compared to untargeted Nuvec¬Æ, demonstrating that Nuvec¬Æ can be directed to specific cell types
¬∑
Broader validation of Nuvec¬Æ
: The findings strengthen the platform's potential as a differentiated delivery system for RNA therapeutics across multiple disease areas, including cancers of high unmet need such as lung and pancreatic cancers
The global RNA therapeutics market was valued at $13.7 billion in 2023 and is forecast to reach $18.0 billion by 2028. Challenges associated with the manufacturing and targeted delivery of RNA therapeutics are known to impact this market growth.
Targeting RNA therapies to specific cells and tissues to maximise efficacy and reduce systemic toxicity is a holy grail for nucleic acid therapeutics developers and is challenging to achieve with established RNA delivery methods.
In parallel to the successful targeting of Nuvec¬Æ particles to cancer cells in collaboration with SRI, N4 Pharma has also demonstrated targeting of Nuvec¬Æ to immune cells using mannose modification in its lead programme, N4 101, which is designed to be an orally delivered treatment for inflammatory bowel disease.
Nigel Theobold, Chief Executive Officer of N4 Pharma, commented:
"Targeting RNA therapies to particular cell types is highly sought after by companies developing RNA therapeutics. We have now demonstrated Nuvec¬Æ's ability to do this in multiple systems, which we believe sets it apart from other RNA delivery methods.
"These recent data from our collaboration with SRI are particularly exciting because they represent the first example of the use of Nuvec¬Æ for the potential treatment of some of the most common and life-threatening cancers.
"N4 Pharma raised capital earlier this year to build out the data to support the key performance claims of Nuvec¬Æ: simultaneous delivery of multiple RNAs; targeting of specific cell types; oral delivery; low immunogenicity; stability; and simple manufacturing. These data generated with SRI are a significant step forward in that process, because of the high demand for targeted therapies to support deal-making and building our own differentiated RNA therapeutics pipeline."
- Ends -
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:
investors.n4pharma.com
https://n4pharma.com/link/P2z1YP
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec¬Æ, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec¬Æ has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec¬Æ platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec¬Æ platform.
For further information on the Company visit
www.n4pharma.com
or sign up at
https://investors.n4pharma.com/auth/signup
.
About SRI
For further information on SRI visit:
https://www.sri.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCZZGMLNLLGKZG
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Notice of Results, Analyst & Investor Presentation</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">19th Sep 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Pharma Investor</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
19 Sep 2025 07:00
RNS Number : 9469Z
N4 Pharma PLC
19 September 2025
19 September 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Notice of Results
Analyst Briefing and Investor Presentation
N4 Pharma plc (AIM: N4P),
the UK biotech developing Nuvec¬Æ, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases
, will announce
its unaudited interim results for the six months ended 30 June 2025 on Thursday, 25 September 2025 and hold the following analyst briefing and investor presentation.
Analyst briefing
An online briefing for analysts will be hosted by
Nigel Theobald, Chief Executive Officer,
at 9.30 am on
Thursday, 25 September 2025
, to review the interim results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at
sarah@northstarcommunications.co.uk
.
Investor presentation
An investor presentation to cover the interim results will be held at 2.00 pm on
Thursday, 25 September 2025
.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am on Wednesday, 24 September 2025 or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet¬†N4 Pharma plc¬†via:
https://www.investormeetcompany.com/n4-pharma-plc/register-investor
Investors who already follow¬†N4 Pharma plc¬†on the Investor Meet Company platform will automatically be invited.
- Ends -
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:
investors.n4pharma.com
https://n4pharma.com/link/y05doe
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec¬Æ, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec¬Æ has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,
protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec¬Æ platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec¬Æ platform.
For further information on the Company visit
www.n4pharma.com
or sign up at
https://investors.n4pharma.com/auth/signup
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
NORSFLFIAEISEIU
                </div>
            </details>
            
            </div>
            
            </div>
            <div style="
                margin-top: 20px;
                padding: 14px 16px;
                background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
                border-radius: 10px;
                font-size: 12px;
                color: #78350f;
                border-left: 3px solid #f59e0b;
                display: flex;
                align-items: flex-start;
                gap: 10px;
            ">
                <span style="font-size: 16px; margin-top: 2px;">üéØ</span>
                <div style="line-height: 1.5;">
                    <strong style="display: block; margin-bottom: 4px;">Trader-Focused Analysis:</strong>
                    Each RNS includes sentiment classification, key data extraction, and trading context. 
                    Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                    <strong style="margin-top: 6px; display: block; font-size: 10px; opacity: 0.8;">
                    ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                    </strong>
                </div>
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
            
            /* ========== MOBILE RESPONSIVE ========== */
            @media (max-width: 768px) {
                body {
                    padding: 10px;
                    font-size: 14px;
                }
                
                .container {
                    margin: 0 auto;
                }
                
                .header-card {
                    padding: 14px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .company-name {
                    font-size: 22px;
                    margin-bottom: 8px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 13px;
                    padding: 6px 12px;
                }
                
                .company-meta {
                    gap: 8px;
                    flex-direction: row;
                    flex-wrap: wrap;
                }
                
                .meta-item {
                    padding: 6px 12px;
                    font-size: 12px;
                    gap: 6px;
                }
                
                .meta-icon {
                    font-size: 14px;
                }
                
                .score-hero {
                    padding: 20px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .action-display {
                    font-size: 18px !important;
                    margin-bottom: 12px;
                }
                
                .scores-row {
                    gap: 16px;
                    margin: 20px 0;
                    justify-content: center;
                    flex-wrap: wrap;
                    display: flex;
                }
                
                .score-circle {
                    width: 110px;
                    height: 110px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 32px;
                }
                
                .score-label {
                    font-size: 10px;
                    margin-top: 4px;
                }
                
                .timing-badge-large {
                    padding: 10px 20px;
                    font-size: 14px;
                    margin: 12px 0;
                }
                
                .thesis-line {
                    font-size: 14px;
                    padding: 12px;
                    margin-top: 12px;
                }
                
                .factors-list {
                    grid-template-columns: 1fr;
                    gap: 10px;
                    margin-top: 12px;
                }
                
                .factor-item {
                    padding: 12px;
                    font-size: 12px;
                    gap: 8px;
                }
                
                .factor-icon {
                    font-size: 16px;
                }
                
                .cards-grid {
                    grid-template-columns: 1fr;
                    gap: 12px;
                    margin-bottom: 12px;
                }
                
                .card {
                    padding: 16px;
                    border-radius: 12px;
                }
                
                .card-title {
                    font-size: 14px;
                    margin-bottom: 12px;
                    gap: 8px;
                }
                
                .card-icon {
                    font-size: 18px;
                }
                
                .stat-row {
                    padding: 8px 0;
                    flex-wrap: wrap;
                    gap: 10px;
                }
                
                .stat-label {
                    font-size: 12px;
                }
                
                .stat-value {
                    font-size: 14px;
                }
                
                .rally-badge {
                    padding: 4px 10px;
                    font-size: 10px;
                }
                
                .risk-indicator {
                    gap: 10px;
                    padding: 12px;
                    flex-wrap: wrap;
                }
                
                .risk-icon {
                    font-size: 20px;
                }
                
                .reason-item {
                    padding: 12px;
                    margin-bottom: 10px;
                }
                
                .tag {
                    padding: 3px 8px;
                    font-size: 10px;
                }
                
                .footer {
                    padding: 12px;
                    font-size: 11px;
                    margin-top: 12px;
                    border-radius: 12px;
                }
                
                .alert-box {
                    padding: 12px;
                    margin: 10px 0;
                }
            }
            
            @media (max-width: 480px) {
                body {
                    padding: 8px 6px;
                }
                
                .header-card {
                    padding: 10px;
                    margin-bottom: 10px;
                    border-radius: 8px;
                }
                
                .company-name {
                    font-size: 18px;
                    margin-bottom: 6px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 11px;
                    padding: 3px 8px;
                }
                
                .company-meta {
                    gap: 4px;
                    flex-direction: column;
                }
                
                .meta-item {
                    padding: 4px 6px;
                    font-size: 11px;
                    background: rgba(247, 250, 252, 0.7);
                }
                
                .score-hero {
                    padding: 12px;
                    margin-bottom: 10px;
                    border-radius: 12px;
                }
                
                .score-circle {
                    width: 70px;
                    height: 70px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 22px;
                    font-weight: 800;
                }
                
                .score-label {
                    font-size: 7px;
                    margin-top: 2px;
                }
                
                .scores-row {
                    flex-direction: column;
                    gap: 10px;
                    margin: 12px 0;
                    align-items: center;
                }
                
                .timing-badge-large {
                    padding: 6px 12px;
                    font-size: 11px;
                    margin: 10px 0;
                }
                
                .thesis-line {
                    font-size: 11px;
                    padding: 8px;
                    line-height: 1.3;
                }
                
                .card {
                    padding: 10px;
                    margin-bottom: 8px;
                    border-radius: 8px;
                }
                
                .card-title {
                    font-size: 12px;
                    margin-bottom: 8px;
                    font-weight: 700;
                }
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-01-21 ‚Ä¢ CrashDash APEX Engine (Advanced Pattern EXploration)<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
            <div style="margin-top: 12px; padding-top: 12px; border-top: 1px solid #e5e7eb; font-size: 11px; color: #999; line-height: 1.5;">
                <strong>APEX</strong> is a CrashDash AI-powered quantitative intelligence platform that analyzes multi-source market signals using advanced pattern recognition. Designed for professional traders and institutional users, it synthesizes technical, sentiment, and fundamental data into actionable market profiles‚Äîready for seamless integration into workflows.
            </div>
        </div>

    </div>
</body>
</html>